Keywords: sepracor, files, nda, xopenex, hfa, mdi, says

Sepracor files NDA for Xopenex HFA MDI

Article | 24 May 2004

Print This

Sepracor says it has submitted a New Drug Application to the US Food and Drug Administration for Xopenex HFA (levalbuterol ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in